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Tobacco-Smoking-Related Differential DNA Methylation:
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Lutz P. Breitling,1,* Rongxi Yang,2,4 Bernhard Korn,3,5 Barbara Burwinkel,2,4 and Hermann Brenner1
Tobacco smoking is responsible for substantialmorbidity andmortality worldwide, in particular through cardiovascular, pulmonary, and
malignant pathology. CpG methylation might plausibly play a role in a variety of smoking-related phenomena, as suggested by candi-
date gene promoter or global methylation studies. Arrays allowing hypothesis-free searches on a scale resembling genome-wide studies
of SNPs have become available only very recently. Methylation extents in peripheral-blood DNA were assessed at 27,578 sites in more
than 14,000 gene promoter regions in 177 current smokers, former smokers, and those who had never smoked, with the use of the
Illumina HumanMethylation 27K BeadChip. This revealed a single locus, cg03636183, located in F2RL3, with genome-wide significance
for lower methylation in smokers (p ¼ 2.683 1031). This was similarly significant in 316 independent replication samples analyzed by
mass spectrometry and Sequenom EpiTyper (p ¼ 6.333 1034). Our results, which were based on a rigorous replication approach, show
that the gene coding for a potential drug target of cardiovascular importance features altered methylation patterns in smokers. To date,
this gene had not attracted attention in the literature on smoking.Introduction
Epigenetic variations of DNA, particularly the attachment
of methyl groups to cytosine bases neighbored by guanine
(CpG sites), are an important source of variation and regu-
lation in the genome.1–3 Scientists have only started to
unravel the diversity of these modifications with the
advent of pertinent high-resolution technologies.2,4 It is
assumed that epigenetic variation plays a significant role
in complex multifactorial diseases.3 It appears compelling
that CpG methylation could account for some of the
‘‘missing’’ heritability not explained by sequence varia-
tion,5 but associating methylation with complex pheno-
types, especially outside the field of malignancy, has
been very difficult.6
Whereasmethods for assessingmethylation at candidate
gene loci and for estimating overall methyl contents of
DNA have been available for some time, genome-wide
arrays for the study of interindividual variations inmethyl-
ation patterns with locus-specific resolution have been
added to the repertoire of investigators only very recently.7
This development resembles the first establishment of
genome-wide SNP arrays, which was a major prerequisite
for successfully elucidating the genetic architecture of
many complex diseases.8,9 With large numbers of candi-
date loci being investigated and increasing the danger of
false-positive findings, independent replications have
been recognized as crucial for ensuring the validity of
SNP associations, including those discovered in genome-
wide approaches.9–11
Tobacco smoking is a leading cause of disease and
premature death.12,13 Through nicotine, it exerts an
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the promotion of smoking cessation clearly remains imper-
ative, better understanding the pathophysiological
processes linking tobacco smoking and its sequelae could
yield opportunities to positively influence disease risk in
the large population of continuing smokers.
Alterations in DNAmethylation are one possible mecha-
nism potentially mediating the harmful effects of tobacco
smoking. Smoking has, for example, been associated with
altered global methylation16,17 and differential methyla-
tion extent in several cancer-related genes.18,19,20 Whereas
the majority of studies have focused on cancer-related
issues and cancer-affected populations, a rare comparison
of noncancer patientsmade up of heavy smokers and those
who had never smoked (‘‘never smokers’’) found candidate
genemethylation to be significantly less frequent in the 30
never-smoking subjects.21 Nicotine itself has been shown
to influence not only the expression of DNA methyltrans-
ferase 1, an enzyme crucial to DNA methylation, but also
promoter methylation levels in GABAergic neurons,
providing a plausible link to nicotine addiction.22
Given the recent accessibility of genome-wide locus-
specific methylation methodology7 and previous support
for a role of methylation changes in smoking-related
pathologies,16,19,21 we conducted a genome-wide screen
for CpG sites that are differentially methylated by
tobacco-smoking status in peripheral-blood DNA.
Subjects and Methods
Study Participants, Data, and Sample Collection
Study subjects were selected from participants of the general popu-
lation-basedepidemiological ESTHERstudyconducted insouthwestrch Center, D-69120 Heidelberg, Germany; 2Molecular Epidemiology C080,
Proteomics Core Facilities, German Cancer Research Center, D-69120 Hei-
stetrics and Gynecology, University of Heidelberg, D-69115 Heidelberg,
5128 Mainz, Germany
Genetics. All rights reserved.
011
Table 1. Characteristics of the Study Populations
Sample Type Phenotype Target N Assayeda Women Men
Discovery Roundb
Heavy smoker smoking R 20 cigarettes per day at ages 30 and 40 and at enrollment 60 65 30 35c
Former smoker abstinent for past 10þ years, but smoking R 20 cigarettes per day before 60 56 28 28
Never smoker lifetime smoking % 100 cigarettes, never regularly smoking 60 56 29 27
Total 180 177d 87 90
Replication Rounde
Heavy smoker as above 100 95 41 54
Former smoker as above 100 97 36 61
Never smoker as above 128 124 51 73
Total 328 316 128 188
a Because of the strict demands on phenotypes and availability of DNA, former and current female heavy smokers essentially presented all such ESTHER23 samples
eligible in the discovery round (rather than a random subset), whereas in the replication round this was the case for all groups but never smokers and current male
heavy smokers.
b Peripheral-blood DNA extracted manually by the phenol method.
c Including five subjects who were self-reportedly abstinent but had serum cotinine > 10 ng/ml.
d One sample excluded before application of the 27K methylation assay, two samples excluded during postassay quality control.
e Peripheral-blood DNA extracted with the use of Invisorb kits (Invitek).Germany.23 Eligibility for this methylation study was restricted to
participants aged 50–60 years (in order to avoid confounding of
our analyses by potential age-related changes in methylation) for
whomblood samples drawn at baseline by their general practitioner
andmailed to the study centerwere available; whose smoking status
based on standardized self-administered questionnaires could be
classified as never having smoked, former heavy smoker, or current
heavy smoker; who never smoked tobacco products other than
cigarettes; who reported nodiagnosis of cancer; and for whom suffi-
cient DNA had been extracted from peripheral blood. Study proce-
dures conformed to the protocol approved by the ethics committee
of theUniversity ofHeidelberg and themedical board of the State of
Saarland. All participants gave written informed consent.
In addition to smoking-related data, alcohol consumption was
assessed as part of a standardized self-administered questionnaire
(items pertaining to average weekly intake of beer, wine, and
liquors, reported in common consumption units and transformed
into gram alcohol per week). The body mass index (BMI) was
derived from body height and weight measurements recorded by
the participant’s physician at recruitment.
The smoking phenotypes were defined tomaximize the contrast
between groups, and current tobacco abstinence was validated by
cotinine immunoassay (Immundiagnostik, Bensheim), because
smoking behavior tends to be underreported.24 Details of the
phenotype definitions and distributions in the 180 subjects exam-
ined for the genome-wide discovery round and of the additional
328 subjects used for replication purposes are presented in Table 1.Infinium 27K Methylation Assay
For the discovery round, the HumanMethylation27 BeadChip,
using Infinium technology25 for genome-wide DNA methylation
screening, was employed.7,26 In brief, genomic DNA (500 ng)
from each sample was treated by bisulfite conversion with the
EZ-96 DNA Methylation Kit (Zymo Research) according to manu-
facturer recommendations, and subjected to whole-genome
amplification. After enzymatic fragmentation, about 200 ng
DNA was applied to BeadChips (Illumina).The AmDuring hybridization, the DNA molecules anneal to locus-
specific DNA oligomers linked to individual bead types. The
two bead types correspond to each CpG locus—one to the meth-
ylated state and the other to the nonmethylated state. Allele-
specific primer annealing is followed by single-base extension
using DNP- and Biotin-labeled ddNTPs. After extension, the
array is fluorescently stained and scanned, and the intensities
of the nonmethylated and methylated bead types are measured.
DNA methylation values, described as ‘‘beta values,’’ are recorded
for each locus in each sample and represent the ratio of the
intensity of the methylated bead type to the combined locus
intensity.
Quality control conducted according to manufacturer instruc-
tions included assessment of DNP and Biotin staining, hybridiza-
tion, target removal, extension, bisulfite conversion, G/T
mismatch, negative and nonpolymorphic controls, and correla-
tion cluster analysis. The various control procedures supported
an appropriate efficiency, sensitivity, and specificity of the indi-
vidual assay steps without remarkable deviations from optimal
performance. Two samples, however, were excluded because of
aberrant correlation clustering suggesting specific problems with
the sample material of these two individuals.Sequenom MALDI-TOF Mass Spectrometry
SequenomMALDI-TOFmass spectrometry (Sequenom)was used in
thevarious replicationefforts. Inbrief,DNAbisulfite conversionwas
performed by the EZ-96 DNA Methylation Gold Kit (Zymo
Research). The bisulfite-specific primers for the PCR aimed at the
replication of the main hit of the genome-wide discovery round
were 50-aggaagagagGGTTTATTAGTAGTATGGTGGAGGG-30 (sense)
and 50-cagtaatacgactcactatagggagaaggctCCCAAACCAAATCTATAC
CAATAAC-30 (antisense). Uppercase letters indicate the sequence-
specific regions, whereas the nonspecific tags are shown in lower-
case letters.
For the additional investigation of methylation patterns in the
neighboring region, two additional amplicons were examined
(see Figures S1 and S2 available online). These were obtainederican Journal of Human Genetics 88, 450–457, April 8, 2011 451
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Figure 1. Mixed Linear Regression p Values of the Sex-Adjusted
Association of Smoking Status with Methylation Intensities at
27,578 CpG Sites
–log10(P) versus –log10(rank) plot.with the use of the primers 50-aggaagagagTGGTTAGTAGGGG
TAGGAAATAGTTTA-30 (sense) and 50-cagtaatacgactcactataggga
gaaggctCCTCCACCATACTACTAATAAACCTC-30 (antisense) for
the first amplicon and primers 50-aggaagagagTTTTTGTTGGT
TATGTTGTTGTGTT-30 (sense) and 50-cagtaatacgactcactatagggagaa
ggctCAACCTTCCCCACTTTATATCACTA-30 (antisense) for the
second amplicon.
The PCR products were treated according to the standard
protocol (Sequenom EpiTyper Assay) by SAP treatment and
T-cleavage reaction. The samples were then cleaned by Resin and
were dispensed to a 384 SpectroCHIP by Nanodispenser. The
chip was read by a Bruker Autoflex Mass Spectrometer system.
Data were collected with the use of SpectroACQUIRE v3.3.1.3 soft-
ware and visualized with MassARRAY EpiTyper v1.0 software.
Statistical Analysis
Medians and interquartile ranges were used for the description of
methylation intensities. A median methylation intensity of 0.83
in smokers, for example, would indicate that in 50% of the
smokers a proportion% 0.83 of the individual’s DNA was methyl-
ated at the respective locus, whereas in the remaining 50%
a proportion > 0.83 of the DNA was methylated.
In the discovery round, data were analyzed by modeling the
methylation at each individual CpG site as quantified by the Illu-
mina ‘‘beta value’’ by mixed linear regression with sex and
smoking stratum (never, former, or heavy smoker) as independent
variables and the inclusion of a random batch effect. The overall
results were summarized in a –log10(P) versus –log10(rank) plot,
in which a straight line would be expected in the absence of any
association betweenmethylation extents and smoking behavior.27
Furthermore—because nonnormal distributions were assumed to
occur—we also analyzed the data by applying the nonparametric
Kruskal-Wallis test for differences in methylation by smoking
stratum, analyzing women and men separately. The most signifi-
cant locus was carried forward for replication.
Because the HumanMethylation27 assay was always applied to
groups of 12 samples at a time, we ensured that individuals of
both sexes and all three smoking categories were represented in
each such batch. Because ‘‘batch’’ thus was not associated with
the exposure, sometimes even significant batch effects had very
limited confounding potential. For example, the batch effect for
the main hit described below had a likelihood ratio test p value
of 3.14 3 106 (based on a 1:1 mixture of c2 distributions with
0 and 1 degrees of freedom28) but its inclusion in the model did
not relevantly affect the association of methylation with smoking
(Pno batch effect ¼ 1.14 3 1027, Pincluding batch effect ¼ 2.68 3 1031).
In the validation and replication analyses based on mass spec-
trometry data, methylation intensities were analyzed by linear
regression adjusted for age and sex and by sex-specific Kruskal-
Wallis testing as outlined above.
Because of a lack of prior data on the expected distributions of
methylation levels measured by the discovery assay and because
it was not clear what would constitute the smallest relevant differ-
ence in methylation, no formal sample-size calculations were
conducted.Results
Discovery Round: Illumina 27K Analysis
The 177 subjects successfully characterized in the
discovery had a mean 5 standard deviation (SD) age of452 The American Journal of Human Genetics 88, 450–457, April 8, 254 5 3 years, and 90 (51%) were male (Table 1, top). Of
27,578 CpG sites assayed, 87.6% had complete data,
98.4% and 99.4% had % 1 and % 2 missing values, and
only 0.1% had 12 or more missing values. This corre-
sponded to a median of 18 (interquartile range: 10–30)
missing values per subject.
Figure 1 shows the distribution of the mixed linear
regression p values for each locus for the smoking stratum
variable. Only one locus clearly deviated from this pattern
(cg03636183 in F2RL3 [MIM 602779]; Psmoking ¼ 2.68 3
1031). Note that a conservative adjustment for multiple
testing using the Bonferroni method and the standard
type I error rate of 0.05 would result in a cutoff for
genome-wide significance of p ¼ 0.05/27,578 loci ¼
1.81 3 106. The same locus reassuringly also showed
the most significant group differences on the basis of the
Kruskal-Wallis tests (Pmales ¼ 5.75 3 109, Pfemales ¼
3.08 3 1011; Table 2).
The regression model suggested neither sex differences
(Psex ¼ 0.63) nor a smoking 3 sex interaction (Pinteraction ¼
0.97) regarding methylation at this locus. Additional
adjustment for age (Page ¼ 0.00065), alcohol consumption
(Palcohol ¼ 0.99), or BMI (PBMI ¼ 0.32) did not change the
results substantially (Psmoking ¼ 3.26 3 1031, 6.40 3
1028, and 1.46 3 1029, respectively). As can be seen in
Figure 2A and Table 2, the association of methylation
with smoking was mainly due to a lower methylation in
heavy smokers as compared to never smokers, with former
smokers showing a distribution close to the methylation
intensities seen in never smokers (Kruskal-Wallis test of
never versus former smokers: Pfemales ¼ 0.11, Pmales ¼
0.011).
Discovery Round: Sequenom Validation
The differential methylation at cg03636183 was validated
by personnel blinded to 27K results and smoking status
who reanalyzed cg03636183 and flanking CpG sites in011
Table 2. Loci that Showed the Most Significant Differential Methylation by Smoking Status on the Basis of the Different Analytical
Approaches Taken
CpG Site Gene (Chromosome) Psmoking p Value Ranks
a
Median (IQR) Methylationb
Never Smokers Former Smokers Current Smokers
Order and Psmoking of Mixed Linear Regression
cg03636183 F2RL3 (19p12) 2.68 3 1031 1 1 1 0.95 (0.94–0.96) 0.94 (0.90–0.95) 0.83 (0.78–0.88)
cg19859270 GPR15 (3q11.2-q13.1) 4.89 3 106 2 7 83 0.93 (0.91–0.94) 0.92 (0.89–0.94) 0.89 (0.86–0.91)
cg02564523 ORAI2 (7q22.1) 1.62 3 105 3 418 9 0.21 (0.18–0.23) 0.21 (0.18–0.28) 0.17 (0.13–0.20)
cg09155905 FNDC8 (17q12) 2.00 3 105 4 8 138 0.24 (0.21–0.25) 0.20 (0.16–0.25) 0.19 (0.15–0.22)
cg09084200 NCAPD3 (11q25) 2.25 3 105 5 198 2 0.15 (0.12–0.16) 0.13 (0.11–0.15) 0.11 (0.09–0.14)
Order and Psmoking of Kruskal-Wallis Test in Females
cg03636183 F2RL3 (19p12) 3.08 3 1011 1 1 1 0.95 (0.94–0.97) 0.94 (0.92–0.96) 0.84 (0.78–0.88)
cg08504583 SLAIN1 (13q22.3) 2.16 3 105 8 2 1343 0.59 (0.50–0.63) 0.64 (0.55–0.69) 0.69 (0.64–0.75)
cg24833277 FAM83A (8q24.13) 7.33 3 105 389 3 15,610 0.88 (0.85–0.91) 0.92 (0.88–0.93) 0.92 (0.90–0.92)
cg21919219 AMY1A (1p21) 1.01 3 104 568 4 19,056 0.83 (0.81–0.84) 0.85 (0.83–0.86) 0.83 (0.82–0.84)
cg12251508 RBM3 (Xp11.2) 1.90 3 104 10,720 5 7405 0.49 (0.47–0.51) 0.45 (0.41–0.48) 0.44 (0.40–0.48)
Order and Psmoking of Kruskal-Wallis Test in Males
cg03636183 F2RL3 (19p12) 5.75 3 109 1 1 1 0.95 (0.94–0.96) 0.94 (0.90–0.95) 0.82 (0.77–0.87)
cg09084200 NCAPD3 (11q25) 2.58 3 105 5 198 2 0.15 (0.13–0.16) 0.13 (0.11–0.15) 0.11 (0.10–0.14)
cg18329036 CRLS1 (20p13-p12.3) 9.52 3 105 132 6206 3 0.03 (0.03–0.04) 0.04 (0.03–0.04) 0.03 (0.02–0.03)
cg21939482 C7orf70 (7p22.1) 1.21 3 104 1854 15,287 4 0.02 (0.02–0.02) 0.02 (0.02–0.02) 0.01 (0.01–0.02)
cg04541293 PTPRT (20q12-q13) 1.34 3 104 20,878 1422 5 0.16 (0.13–0.18) 0.19 (0.17–0.25) 0.13 (0.12–0.16)
a Psmoking value ranks of the mixed linear regression, Kruskal-Wallis tests in females, and Kruskal-Wallis tests in males, respectively.
b Values in rows ordered by Kruskal-Wallis tests present medians in only the females and only the males, respectively.the discovery round samples via the Sequenom MALDI-
TOF mass spectrometry method.
The DNA segment of the cg03636183-harboring region
of F2RL3 amplified for this purpose and analyzed by
MassArray consisted of the sequence 50-GGTTCATCAG
CAGCATGGTGGAGGGCAGCCGAGGTGCCTGCGTGGC
CAGCACCCACAGCGCCAGCCCATTGGCCGGCAGCCC
CACCACCAGGACCAGCCCATAGAGGGCGGGCACCAG
CCTGGTGGGCACCCAGCCCAGAAGCAGTGCCCGTGABA
median (IQR)=0.95 (0.94-0.96)
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Figure 2. Distribution of Methylation Intensities by Smoking Statu
(A) Histograms of ‘‘beta values’’ obtained in the 27K genome-wide sc
(B) cg03636183 methylation extent as determined by the Sequenom
samples.
(C) cg03636183 methylation measured by the Sequenom MassArray
The AmGCTGTCCGGGAGCTCCAGGGTGTCACTGTCATTGGCA
CAGACTTGGCCTGGG-30. As indicated by the use of
underlining, this amplicon contained seven CpG sites
overall. The one referring to cg03636183 is written in
bold, an aberrant one (that is, less correlated with the other
sites; see below) is written in italics, and one site for which
methylation levels could not be measured because of too-
low mass in the MassArray is written in strikethrough
font. Note, furthermore, that the 4th and 6th CpG siteC
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MassArray, validating the discovery measurements in the same
in a nonoverlapping replication sample set.
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Figure 3. Example Results of the Sequenom MassArray Analysis of cg03636183 Methylation Extents
The graphs show the detection intensity (y axis) of amplicon fragments after base-specific cleavage. The latter results in fragments of
different masses (x axis) for originally methylated and nonmethylated CpG sites. The proportion of methylated CpG at this locus
can thus be determined by the ratio of detection intensities at masses corresponding to fragments originating frommethylated and non-
methylated CpG sites (blue and red vertical lines, respectively). The graphs originating from samples with 17%, 59%, and 98%
methylation at cg03636183 (from left to right) show clearly distinguishable peaks.were cleaved into fragments with the same mass and we
thus could not distinguish them because they yielded
a single overlapping signal in the mass spectrometry anal-
ysis. Figure 3 provides example mass spectrometry results
of cg03636183.
Methylation at the site corresponding exactly to
cg03636183 showed a Spearman correlation of 0.82 (p <
0.0001) with the 27K measurements. Except for the one
aberrant site, the CpG loci covered were highly correlated
with cg03636183 and among each other (coefficients R
0.72; all p < 0.0001). As can be seen in Figure 2B, the
MassArray results featured a wider range than the 27K
measurements for this locus, suggesting somewhat differ-
ent assay dynamics at lower methylation levels, but the
overall pattern of group differences with pronounced
hypomethylation in current smokers was unambiguously
preserved (Psmoking ¼ 1.07 3 1028). Methylation at the
other well-measureable loci in this amplicon showed
similar associations with smoking (Psmoking ranging from
4.81 3 1027 to 4.81 3 1031).
Discovery Round: Neighboring CpG Island Analysis
To gain further insight into the extent of methylation
changes at the F2RL3 locus, we analyzed two additional
amplicons covering the adjacent CpG island by Sequenom
MassArray (Figures S1 and S2), using 79 samples of the
discovery study. Only the methylation of the two CpGs
most closely located near our main hit (separated from
cg03636183 by 41 bp, producing a joint peak in the mass
spectrometry) showed a pronounced correlation with
cg03636183 (Spearman coefficient ¼ 0.49, p < 0.0001).
Independent Replication Analysis
The same SequenomMassArray assay used during the vali-
dation of the main hit described above was used to analyze
328 nonoverlapping subjects, of whom 316 (96.3%)
could be successfully characterized (Table 1, bottom). The
mean5 SD agewas 555 3 years, and 188 (59%)weremale.
The correlation pattern between the loci was similar to
that seen in the main-hit amplicon in the discovery
samples; i.e., the CpG sites covered were all strongly corre-
lated with each other (all coefficients R 0.50 and p <
0.0001, except those referring to the previously mentioned454 The American Journal of Human Genetics 88, 450–457, April 8, 2aberrant site), although the Spearman coefficients were
slightly smaller than those in the discovery samples. The
pronounced association with smoking status could be
confirmed in both the parametric and nonparametric
approaches (linear regression: Psmoking ¼ 6.33 3 1034;
Kruskal-Wallis: Pmales ¼ 9.20 3 1014, Pfemales ¼ 2.22 3
1012). The distribution of methylation intensities was
very similar to that observed in the discovery samples,
with heavy smokers showing the lowest levels and never
smokers the highest levels (Figure 2C). The distribution
seen in former smokers also more resembled the pattern
seen in never smokers, although a tendency toward lower
methylation intensities was again suggested (Kruskal-
Wallis test of never versus former smokers: Pfemales ¼
0.0026, Pmales ¼ 0.20).Dose-Response Explorations
In additional analyses, there was a tendency of
cg03636183 methylation to decrease with increases in
the cumulative amount of cigarette consumption among
current smokers in the study (measured in pack years;
Spearman coefficient ¼ 0.18, p ¼ 0.031, n ¼ 150) and
a tendency for cg03636183 methylation to increase with
increasing duration of abstinence in former smokers
(Spearman coefficient ¼ 0.10, p ¼ 0.21, n ¼ 152), which
was slightly more pronounced for another CpG in the
same amplicon (Spearman coefficient ¼ 0.18, p ¼ 0.026;
coefficients controlled for sex and study round).Discussion
The present 27K discovery and replication study of meth-
ylation changes according to smoking behavior identified
one single locus strongly differentially methylated
between exposure groups, a finding fully replicable in an
independent, nonoverlapping sample set. Given that the
hit was located in a gene of cardiovascular relevance that
is being investigated as a drug target,29,30 these results
open up a variety of research avenues for future studies.
The locus significantly less methylated in smokers is
designated to the coagulation factor II receptor-like 3
gene (F2RL3), coding for protease-activated receptor-4011
(PAR4). Intriguingly, this protein has not been discussed or
even mentioned in the tobacco smoking literature to date.
It has been shown to introduce platelet activation and to
affect other cardiovascular functions such as intimal
hyperplasia and inflammation,29 all of which are con-
sidered plausible mechanisms of smoking-induced
pathology.31 Smoking is indeed considered to detrimen-
tally affect clotting through altered endothelial function,
platelet adhesiveness and aggregation, and fibrinogen
levels.32 Platelet aggregability has interestingly been
shown to improve substantially after only 2 weeks of
tobacco abstinence, at least in young smokers.33 In this
context, future studies need to corroborate the function-
ality and clinical importance of the differential methyla-
tion described here. Given the prominent detrimental
role of smoking in public health, it would appear worth-
while to call for large-scale, multidisciplinary and collabo-
rative efforts in this regard, allowing a timely elucidation of
the potential emerging from the present finding.
At present, epigenetic studies favor complex bioinfor-
matics andmultivariate data analyses ofmethylation signa-
tures over many loci,34–36 contrasting the dearth of
convincingly replicated specific discoveries from genome-
wide epigenetic approaches. The findings reported here
clearly demonstrate that locus-specific genome-widemeth-
ylationstudiesapplyingclassical statistical tests inahypoth-
esis-free but strictly stage-wise discovery and replication
fashion along the lines of genome-wide SNP studies8 can
identify replicable and previously unknown locus-pheno-
type associations of high biological plausibility. A larger
number of affected CpG sites might have been expected
on the basis of the less specific associations of smoking
with methylation changes reported in the literature,16–20
although it is not immediately clear how thesewould trans-
late into single CpG signals of genome-wide significance.
Future studies with higher assay coverage—balanced with
increased sample sizes to improve power despite more
extrememultiple testing—might turn up important signals
in addition to the single outstanding hit described here.
Whereas it appears unlikely that cell-type-specific meth-
ylation differences were responsible for our findings—
changes in blood composition would need to be exces-
sively drastic in order to explain the pronounced observa-
tion described and probably should have resulted in some
lineage-related hits—tissue-specific analyses would be of
great interest in the future. The utility of peripheral-blood
DNA might have limitations in this regard, but there are
precedents in whichmethylation patterns in suchmaterial
have been used successfully to distinguish between
subjects with or without disease; for example, subjects
with or without ovarian34 or breast37 cancer. Also note
that, whereas the differential methylation seemed not to
reach into the adjacent CpG island, methylation in ‘‘CpG
island shores’’ has recently been described as being of
particular biological importance.38 In the absence of perti-
nent data on F2RL3, it remains unclear how or to what
extent the rather localized methylation differencesThe Amdescribed here might affect gene regulation. Future studies
certainly should address in detail the functionality of the
differential methylation in F2RL3 in terms of expression,
as well as tissue-specific aspects thereof.
Common limitations of observational studies include the
potential distortion of associations by confounding factors.
Arguably, only a confounder very strongly associated with
both smoking behavior and locus-specific methylation
could result in such a strong signal. Given that sex, age,
BMI, and alcohol consumption were addressed through
restriction, stratification, or adjusted multiple regression,
confounding appears an unlikely—albeit not impossible—
explanation for our findings. Smoking nonetheless does
not necessarily have a direct effect on methylation at the
CpG sites described here, and such an immediate relation-
ship might actually appear rather unlikely given the
pronounced and currently inexplicable specificity of the
association. Given the assumed role of the gene product
for the pertinent biological processes,29 the alteredmethyla-
tion inF2RL3might also reflect smoking-inducedalterations
of, for example, the vascular system and platelet function.
In conclusion, the present 27K methylation study
employed a simple yet rigorous stage-wise design leading
to the discovery of a fully replicable, differentially methyl-
ated CpG in F2RL3 associated with smoking behavior.
Intriguing perspectives lie in the possibility that epigenetic
variability in this gene could be causally involved at a very
initial stage of smoking-related cardiovascular pathology
through the gene’s role in endothelial physiology and
platelet activation.29,31 In this case, better understanding
of its role might open up avenues for preventing the devel-
opment of associated disease in subjects unable to give up
smoking.
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